Pharmadrug Inc.
PHRX
CNSX
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -69.27% | -89.33% | 99.93% | 172.56% | -59.32% |
| Depreciation & Amortization | -- | -- | -- | 3,316.67% | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -72.17% | -99.16% | 126.43% | 210.53% | -63.40% |
| Operating Income | 72.17% | 99.16% | -126.43% | -210.53% | 63.40% |
| Income Before Tax | 40.68% | 66.35% | -203.63% | -660.71% | 89.98% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 40.68% | 66.35% | -203.63% | -580.02% | 89.98% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.68% | 66.35% | -203.63% | -4,857.62% | 65.76% |
| EBIT | 72.17% | 99.16% | -126.43% | -210.53% | 63.40% |
| EBITDA | 78.72% | 103.74% | -123.41% | -195.73% | 63.57% |
| EPS Basic | 70.45% | 83.87% | -61.54% | -4,000.00% | 65.89% |
| Normalized Basic EPS | 66.67% | 78.13% | 0.00% | -655.56% | 30.00% |
| EPS Diluted | 70.45% | 83.87% | -50.00% | -6,373.68% | 65.89% |
| Normalized Diluted EPS | 66.67% | 78.13% | 0.00% | -655.56% | 30.00% |
| Average Basic Shares Outstanding | 104.99% | 97.60% | 86.82% | 46.80% | 0.23% |
| Average Diluted Shares Outstanding | 104.99% | 97.60% | 86.82% | 46.80% | 0.23% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
